ADVANCED MEDICAL EQUIPMENT SPOLKA AKCYJNA
2.06
PLN
-0.04
(-1.90%)
ADVANCED MEDICAL EQUIPMENT SPOLKA AKCYJNA
GPW:AME
(Warsaw Stock Exchange)
Recent
price
2.06
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- Advanced Medical Equipment Spolka Akcyjna is a Poland-based medical technology company that specializes in the research, design, clinical development, and commercialization of non-invasive in vitro diagnostic medical devices. The company focuses on developing breath-analysis diagnostic systems that utilize advanced chemical sensor arrays and analytical algorithms to detect disease-specific biomarkers in exhaled human breath. Its core product portfolio and pipeline comprise Diabetomat, a non-invasive medical diagnostic device engineered to measure blood glucose concentrations and metabolic indicators via breath biomarker analysis, offering an alternative to traditional invasive blood-pricking glucometers; CardioBreath, a diagnostic monitoring device designed for the non-invasive tracking and early detection of heart failure exacerbations through the evaluation of cardiovascular breath markers; integrated proprietary semiconductor and optoelectronic gas sensor modules; bespoke breath sampling and temperature-humidity conditioning chambers; and specialized analytical software for real-time biomarker quantification, data processing, and wireless integration with clinical and personal digital health management platforms. The company primarily targets diabetic patients, cardiovascular patients, hospitals, outpatient diagnostic centers, and specialized healthcare providers across Poland and broader European markets. Founded in 2022, Advanced Medical Equipment Spolka Akcyjna is headquartered in Warsaw, Poland. In recent corporate developments, the company completed its public listing on the NewConnect alternative trading system of the Warsaw Stock Exchange under the ticker AME in September 2024. The company has consolidated full legal ownership of its intellectual property by acquiring seven domestic and international patents governing its breath-analysis technologies and terminating previous licensing arrangements. In addition, the company has completed product compliance testing under the European Radio Equipment Directive (RED) for its Diabetomat platform, secured non-dilutive research and development grant financing through the Polish Agency for Enterprise Development (PARP) under the Smart Pathway European Funds for Modern Economy (FENG) framework, and expanded its clinical development pipeline to address heart failure diagnostics through the CardioBreath development program.